Author

Madeline G Townsend

Brigham and Women's Hospital

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Organism:human· 2 Research Focus:spatial domain detection· 2 Assay:spatial transcriptomics· 2 Approach:statistical model· 2 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Jennifer L. GuerrieroiD· 2 shared Kaoru ShimadaiD· 2 shared Kelly F Zheng· 2 shared Adam NelsoniD· 1 shared Adrienne Gropper WaksiD· 1 shared Arielle Lutterman HeekeiD· 1 shared Ashka Patel· 1 shared Austin Schultz· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Jennifer L. GuerrieroORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Spatial/molecular heterogeneity and treatment response in HER2+ early breast cancer: Translational analyses from the DAPHNe trial

Emily Chen, Ilana Miriam Schlam, Kaoru Shimada, Tianyu Li, Esther Ritah Ogayo, Ashka Patel, Janae Davis, Jia‐Ren Lin, Austin Schultz, Madeline G Townsend, Kelly F Zheng, Carlos Wagner S Wanderley, Ricardo Pastorello, Felicia New, Evelyn Metzger, , Adrienne Gropper Waks

The paper analyzes HER2+ breast cancer using multi-platform data to identify molecular predictors of response to neoadjuvant therapy and highlights intra-tumoral heterogeneity and immune exclusion mechanisms.

bioRxiv · Sep 18, 2026 · PreprintCancer Biology

TALAVE in Breast Cancer: BRCA1/2 Mutation-Dependent Immune Remodeling after PARP Inhibition with Limited Checkpoint Engagement

Filipa C. Lynce, Kaoru Shimada, Claudine J. Isaacs, Xue Geng, Edward T. Richardson, Adam Nelson, Candace Bavette Mainor, Mei Wei, Julie Marie Collins, Paula Raffin Pohlmann, Arielle Lutterman Heeke, Kelly F Zheng, Madeline G Townsend, Nicole Swanson, Lauren M. Sloat, , Jennifer L. Guerriero

The paper shows BRCA-mutant breast cancers respond to PARP inhibitors with immune remodeling, but PD-L1 blockade is ineffective due to spatial separation of PD-L1+ cells and PD-1+ T cells.

bioRxiv · Sep 18, 2026 · PreprintCancer Biology